Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma.

Arachidonic acid metabolism plays an important role in colon carcinogenesis. Cyclooxygenase-2 (COX-2), which catalyzes the rate-limiting step in the synthesis of prostaglandins from arachidonic acids, is known to be up-regulated in colon cancer, and multiple lines of evidence indicate that it is a critical early step in colon carcinogenesis. Recently, 15-lipoxygenase-1, the enzyme that converts arachidonic acid to 15(S)-HETE, was also found to be up-regulated in colon carcinoma. In our previous studies, we cloned a gene that encodes another arachidonic acid-using enzyme, fatty acid CoA ligase 4 (FACL4), and showed that overexpression of this enzyme prevents apoptosis. We have also showed that FACL4 and COX-2 synergistically inhibit apoptosis by reducing the intracellular level of free arachidonic acid. Here, we report that expression of FACL4 is significantly increased in colon adenocarcinoma compared with adjacent normal tissue at both the mRNA and protein levels by quantitative RT-PCR (paired t test, P < 0.015), immunoblot, and immunohistochemical staining. We found that the increase in expression level of FACL4 mRNA relative to control ranged between 2.4- and 54.5-fold; the average fold-increase was 13.4. The increase in FACL4 protein expression is between 2.4- and 65.0-fold. In addition, we found that a higher level of increased FACL4 expression was correlated with well and moderately differentiated adenocarcinoma, whereas no similar correlation was observed with COX-2 expression. The in situ hybridization results indicate that expression of FACL4 is localized predominantly in the colon epithelium but not in the stroma. The onset of FACL4 up-regulation appears to occur during the transformation from adenoma to adenocarcinoma because FACL4 expression was not increased above normal in the three colon adenomas examined. Finally, we observed that a tumor promoter significantly induced FACL4 expression. These findings suggest that the FACL4 pathway may be important in colon carcinogenesis, and that the development of selective inhibitors for FACL4 may be a worthy effort in the prevention and treatment of colon cancer.

[1]  K. Kinzler,et al.  Molecular determinants of dysplasia in colorectal lesions. , 1994, Cancer research.

[2]  Chemoprevention of intestinal polyposis in the APCΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor , 2000 .

[3]  C. Myers,et al.  Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Morrow,et al.  Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. , 1998, Cancer research.

[5]  A. Ristimäki,et al.  Expression of cyclooxygenase-2 in human gastric carcinoma. , 1997, Cancer research.

[6]  G. Zimmerman,et al.  Expression of fatty acid‐CoA ligase 4 during development and in brain , 2000, FEBS letters.

[7]  E. Traer,et al.  Cloning, expression, and chromosomal localization of human long-chain fatty acid-CoA ligase 4 (FACL4). , 1998, Genomics.

[8]  E. Rimm,et al.  Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals , 1994, Annals of Internal Medicine.

[9]  J. Bar-Tana,et al.  Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4α , 1998, Nature.

[10]  K. Kristiansen,et al.  Long-chain acyl-CoA esters and acyl-CoA binding protein are present in the nucleus of rat liver cells. , 2000, Journal of lipid research.

[11]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[12]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[13]  Y. Yatabe,et al.  Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. , 1998, Cancer research.

[14]  J. Shah,et al.  Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. , 1999, Cancer research.

[15]  Jilly F. Evans,et al.  Chemoprevention of intestinal polyposis in the APCΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor , 2000, American Journal of Gastroenterology.

[16]  J. Kondo,et al.  Structure and regulation of rat long-chain acyl-CoA synthetase. , 1990, The Journal of biological chemistry.

[17]  D. Appleton,et al.  A protective effect of sulindac against chemically‐induced primary colonic tumours in mice , 1988, The Journal of pathology.

[18]  R. White,et al.  Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Bordas,et al.  Effects of long-term sulindac therapy on colonic polyposis. , 1991, Annals of internal medicine.

[20]  K. Kinzler,et al.  Molecular diagnosis of familial adenomatous polyposis. , 1993, The New England journal of medicine.

[21]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[22]  S Omura,et al.  Evidence for an essential role of long chain acyl-CoA synthetase in animal cell proliferation. Inhibition of long chain acyl-CoA synthetase by triacsins caused inhibition of Raji cell proliferation. , 1991, The Journal of biological chemistry.

[23]  K. Subbaramaiah,et al.  Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. , 1996, Cancer research.

[24]  K. Honn,et al.  Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Schuler.  Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.

[26]  L. Marnett.  Aspirin and the potential role of prostaglandins in colon cancer. , 1992, Cancer research.

[27]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[28]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[29]  G. Zimmerman,et al.  Intracellular unesterified arachidonic acid signals apoptosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[31]  B. Calvo,et al.  Expression of 15-lipoxygenase-1 in human colorectal cancer. , 1999, Cancer research.

[32]  N. Færgeman,et al.  Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signalling. , 1997, The Biochemical journal.

[33]  S. Meltzer,et al.  Advances in Brief Increased Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Barrett ' s Esophagus and Associated Adenocarcinomas 1 , 2006 .